tara-002
tara-002: developed by 1 company · 1 clinical trial tracked · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Protara Therapeutics, Inc. (TARA) | Phase 3 |
Clinical Trials (1)
A Phase 2a/b Single Arm Open Label Study to Evaluate the Safety and Efficacy of Intracystic Administration of TARA-002 in Participants Between 6 Months to Less Than 18 Years of Age for the Treatment of Macrocystic and Mixed Cystic Lymphatic Malformations
FDA Decisions
Frequently asked questions
Who is developing tara-002?
tara-002 is being developed by Protara Therapeutics, Inc..
How many clinical trials involve tara-002?
BioSniper tracks 1 clinical trial involving tara-002.
What is tara-002's latest FDA decision?
The most recent tracked FDA decision for tara-002 is FDA_Meeting for FDA provided written feedback supporting a registrational design for a controlled trial in BCG-Naïve patients, agreeing intravesical chemotherapy is an acceptable comparator..
Get deeper analysis on tara-002
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis